NASDAQ:FENC Adherex Technologies Q3 2025 Earnings Report $8.57 -0.76 (-8.15%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$8.59 +0.02 (+0.23%) As of 10/10/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Adherex Technologies EPS ResultsActual EPSN/AConsensus EPS $0.16Beat/MissN/AOne Year Ago EPSN/AAdherex Technologies Revenue ResultsActual RevenueN/AExpected Revenue$13.43 millionBeat/MissN/AYoY Revenue GrowthN/AAdherex Technologies Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Adherex Technologies Earnings HeadlinesAdherex Technologies (NASDAQ:FENC) Upgraded to "Buy" at Wall Street ZenOctober 5, 2025 | americanbankingnews.comFennec Pharmaceuticals Inc. (FENC) Q2 2025 Earnings Call TranscriptAugust 19, 2025 | seekingalpha.comMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also brings new risks for retirement savers. Traditional 401(k)s and IRAs may leave investors more exposed than they realize. That’s why a Trump-backed IRS strategy is gaining attention. It allows everyday Americans to reposition their retirement savings into real assets like gold and silver — offering both protection and potential upside. A new 2025 Wealth Protection Guide explains exactly how it works.October 12 at 2:00 AM | American Alternative (Ad)Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business UpdateAugust 14, 2025 | globenewswire.comFennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025August 11, 2025 | globenewswire.comRecent Price Trend in Adherex Technologies (FENC) is Your Friend, Here's WhyJuly 15, 2025 | msn.comSee More Adherex Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adherex Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adherex Technologies and other key companies, straight to your email. Email Address About Adherex TechnologiesFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies (NASDAQ:FENC) and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.View Adherex Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi Deal Upcoming Earnings Fastenal (10/13/2025)America Movil (10/14/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
